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ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative disease that is responsible for up to
80% of all dementia cases. Hallmarks of AD include the presence of beta-amyloid
(Aβ) deposits and twisted strands of abnormal hyperphosphorylated tau forming
neurofibrillary tangles (NFTs), which ultimately lead to damage and death of nerve
cells in the brain. Symptoms of the disease include impairments in cognitive and
functional abilities that gradually worsen as the disease progress. Finally, in advanced
AD, patients become unable to perform basic daily activities, become more
susceptible to infections, and ultimately die. Only five drugs are FDA-approved for
use in AD, which only provide temporary symptomatic relief without capabilities of
modifying the progression of the disease. Tolfenamic acid is a non-steroidal antiinflammatory drug that has the potential for slowing the progression of AD by
inducing the degradation of the transcription factor specificity protein 1 (Sp1). Sp1
regulates the expression of several AD-related genes including amyloid precursor
protein (APP), tau and beta-site APP-cleaving enzyme 1 (BACE1).
To investigate the ability of tolfenamic acid to cross the blood brain barrier (BBB),
multiple approaches were utilized. In silico computational models to predict logBB
and logPS for CNS penetration indicated that tolfenamic acid could transfer passively
through

the

BBB.

In

addition,

immobilized

artificial

membrane

(IAM)

chromatography using a phosphatidylcholine column was utilized for the in vitro
determination of the brain penetration capacity factor [(KIAM/MW4)x1010] of
tolfenamic acid. The results showed that the [(KIAM/MW4)x1010] for tolfenamic acid

was 2.73 indicating its ability to cross the BBB and penetrate into the brain. Upon
intravenous (IV) administration of tolfenamic acid to guinea pigs and mice, LC-MS
analysis revealed the presence of tolfenamic acid in the extracted brain tissue. This in
vivo approach was also used to estimate the brain-to-plasma ratio (Kp) for tolfenamic
acid, which was 0.11. Thus, using in silico, in vitro and in vivo methods, we confirmed
the ability of tolfenamic acid to cross the BBB. The study offers a guide of using
multiple approaches to predict the ability of different compounds to penetrate the
brain.
Next, we investigated the ability of tolfenamic acid to attenuate the cognitive deficits
in a transgenic mouse model of AD, namely R1.40. First, we demonstrated that
hemizygous R1.40 mouse model exhibits spatial working and long-term memory
deficits when tested in the Morris water maze and Y-maze. We found that short-term
administration of tolfenamic acid for 34 days was able to reverse the observed
cognitive deficits in hemizygous R1.40 mice. These mnemonic improvements were
parallel to reductions in SP1 protein, APP expression and protein, and soluble and
insoluble Aβ40-42 levels. These findings suggest that the reductions in the biochemical
markers of AD were also accompanied by functional improvements in the treated
mice.
We further examined the ability of tolfenamic acid to improve spatial learning and
memory as well as to reduce Aβ plaque pathology in old homozygous R1.40.
Homozygous R1.40 mice exhibit cognitive deficits that are accompanied by fibrillar
Aβ deposition in different regions of the brain by the age of 14-15 months. Our

immunohistochemical results indicated that short-term tolfenamic acid treatment for
34 days was able to produce a drastic reduction in Aβ plaque pathology. In addition,
spatial working memory, assessed by the spontaneous alternations in the Y-maze, was
improved by tolfenamic acid treatment. Further, we investigated if tolfenamic acid
would improve the age-related learning and memory impairments in senescent
C57BL/6 mice and we found that treatment with tolfenamic acid for 34 days resulted
in improvements in the spatial reference memory functions as well. The major
findings from these studies suggest that tolfenamic acid crosses the BBB into the
brain, is able to decrease AD-related proteins including Aβ plaques, and is able to
produce mnemonic functional improvements in AD transgenic mouse model and
senescent wild type mice as well. Thus, tolfenamic acid could be proposed as a
disease-modifying therapy for AD via its unique mechanism.
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PREFACE
This dissertation addresses the brain penetration of tolfenamic acid using
multiple approaches as well as it address its effects in altering various AD-related
pathology and improving the mnemonic deficits in a transgenic mouse model of AD
and senescent wild type mice. It discusses the molecular biology, behavioral and
immunohistochemical experiments used to investigate the effects of tolfenamic acid as
a proposed disease-modifying drug candidate for AD.
The dissertation is structured in manuscript format and it comprises three
manuscripts. The first manuscript “The Ability of Tolfenamic Acid to Penetrate the
Brain: A Model for Testing the Brain Disposition of Candidate Alzheimer’s Drugs
Using Multiple Platforms” was published in 2011 in Current Alzheimer Research. The
second manuscript “Reversal of Cognitive Deficits by Tolfenamic Acid is
Accompanied by Reductions in Intermediates Associated with Amyloid pathology in a
Transgenic Mouse Model of Alzheimer’s Disease” is formatted in accordance for
submission to Neurobiology of Aging. The third manuscript “Reduction of β-Amyloid
Deposition and Attenuation of Memory Deficits by Tolfenamic Acid” is formatted in
accordance for submission to Alzheimer’s & Dementia.
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MANUSCRIPT 1

The Ability of Tolfenamic Acid to Penetrate the Brain: A Model for Testing the
Brain Disposition of Candidate Alzheimer’s Drugs Using Multiple Platforms
By
Gehad M. Subaiea, Bothaina H. Alansi, David A. Serra, Maged Alwan, and Nasser
H. Zawia
(Published in Current Alzheimer Research, 2011, 8, 860-867)
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Abstract
Evidence from our laboratory suggests that tolfenamic acid has a potential for slowing
the progression of Alzheimer’s disease (AD) through lowering cortical levels of the βamyloid precursor protein (APP) and its pathogenic amyloid beta (Aβ) intermediates
[1]. In this study, we examined the ability of tolfenamic acid to cross the blood brain
barrier (BBB) by predicting its logBB and logPS values, the indexes of BBB
permeability, using computational models. We also determined, via in vitro methods,
the brain penetration capacity factor [(KIAM/MW4)x1010] using phosphatidylcholine
column chromatography. The obtained logBB, logPS and (KIAM/MW4)x1010 values
predicted that tolfenamic acid can passively transfer into the central nervous system
(CNS). These results were validated in vivo using LC-MS analysis after administration
of tolfenamic acid intravenously to guinea pigs and mice. The present study provides
the first evidence of the ability of tolfenamic acid to cross the BBB and offers a
comparative analysis of approaches used to predict the ability of compounds to
penetrate into the brain.

Keywords: Alzheimer’s disease, blood brain barrier, HPLC, mass spectrometry,
tolfenamic acid.
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1.

Introduction

Alzheimer’s disease (AD), a progressive neurodegenerative disease marked by
dementia evolving till death, is characterized by plaques. These plaques are composed
mainly of amyloid beta (Aβ) peptides that result from the cleavage of β-amyloid
precursor protein (APP) by the enzyme β-site APP cleaving enzyme 1 (BACE1)
followed by γ-secretase [2]. Specificity protein 1 (Sp1) is a transcription factor that is
involved in co-activation of APP transcription and regulation of BACE1 expression
[3, 4] and is critical for the activation of the human APP promoter [5]. Tolfenamic
acid is a non-steroidal anti-inflammatory drug (NSAID) used in Europe for the
treatment of migraine, and has been found to degrade the transcription factors Sp1,
Sp3, and Sp4 proteins and thus inhibiting the growth of pancreatic tumors by
diminishing the expression of vascular endothelial growth factor (VEGF) [6].
Data from our lab indicate that tolfenamic acid lowers cortical Sp1 protein (SP1)
levels and consequently APP expression and its plaque-forming Aβ products [1].
Compounds designed to exhibit their mode of action in the central nervous system
(CNS) need to be assessed for their ability to cross the blood brain barrier (BBB) and
thus we conducted several studies to examine the ability of tolfenamic acid to
penetrate into the brain.
There are various in silico, in vitro and in vivo models that are used in drug discovery
for the assessment of the ability of potential drug candidates to transfer into the CNS
[7]; however, few studies have compared the potential of these methods using a single
compound tested across platforms. In this study, we studied the brain transfer potential
3

of tolfenamic acid using three approaches. Comparison of these approaches offers a
guide for any study that seeks to examine brain penetration of compounds and also
provides data relevant for future screening strategies of candidate drugs tested for AD
therapeutics.
First, we utilized an in silico computational model using prediction software
developed by Advanced Chemistry Development (ACD) to predict and analyze the
indexes of BBB permeability logBB and logPS of tolfenamic acid. Reference
adrenergic blockers of known CNS classification such as propranolol, a compound
known for its ability to cross the BBB [8], timolol and atenolol, both of which poorly
cross the BBB [9, 10], were used. Second, The Immobilized Artificial Membrane
(IAM) chromatography utilizing phosphatidylcholine column method [11] was used as
a valid non cell-based in vitro predictor of BBB permeation. The IAM surface of the
column resembles the lipid phase of the brain capillary endothelium and is chemically
and thermally stable for chromatographic conditions [7]. Finally, the in silico and in
vitro BBB permeation predictions of tolfenamic acid were validated using in vivo
analysis where mice and guinea pigs, the two animal models we conduct our studies
on, were administered tolfenamic acid intravenously followed by analysis of mass
spectra data and calculating the brain-to-plasma concentration ratio, Kp, of tolfenamic
acid after a single time point [7].
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2. Materials and Methods
2.1. Materials and Standards
Tolfenamic acid, propranolol, timolol, diclofenac sodium, potassium chloride (KCl),
monobasic potassium phosphate (KH2PO4) and sodium chloride (NaCl) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide 97% pellets
and formic acid were obtained from Fisher Scientific (Fair Lawn, NJ, USA).
Hydrochloric acid (HCl) 37%, acetonitrile, sodium phosphate dibasic dodecahydrate
(Na2HPO4.12H2O), and water were HPLC grade from Acros Organics (Morris Plains,
NJ, USA). Other chemicals and reagents were of analytical grade.
2.1.1. In silico Computational Approach
LogBB and LogPS were calculated for tolfenamic acid, propranolol, timolol and
atenolol from values obtained through using two prediction software developed by
ACD (Toronto, Ontario, Canada). Values used to calculate logBB were obtained from
ACD/ChemSketch 12.0 software [12] which included octanol-water partition
coefficient (LogP). Other brain transfer descriptors including molecular weight,
hydrogen bond donor/acceptor number (Hd and Ha), polar surface area (PSA), free
rotatable bond (FRB) and acid dissociation constant (pKa) were obtained from
literature [13]. LogPS values were obtained utilizing ACD/ADME Suite software [14].
2.1.2. In vitro Experiment
2.1.2.1. HPLC Conditions

5

Hitachi analytical HPLC system consisting of an L-7100 low- pressure gradient pump,
a 4-channel degasser, an L-7200 sequential auto-sampler, and a high sensitivity diode
array detector (190-800 nm) was used. This system is controlled by a D-7000 HPLC
system manager software package. The HPLC apparatus was fitted with an
analytically sized (10 cm x 4.6 mm) IAM.PC.DD2 column from Regis technologies
(Morton Grove, IL, USA). The Dulbecco’s phosphate-buffered saline (DPBS)
consisted of 2.7 mM KCL, 1.5 mM KH2PO4, 137 mM NaCl, and 8.1 mM Na2HPO4.
The mobile phase consisted of acetonitrile and DPBS (20:80 v/v, pH of 5.5). Samples
were eluted using the mobile phase with a flow rate of 0.5 ml/min at 37°C, and UV
absorption at 210 nm.
2.1.2.2. Selection of Reference Compounds
Propranolol and timolol were used as reference compounds for the in vitro experiment.
Propranolol is classified in the literature as a high brain penetration (CNS+) compound
[8] while timolol is classified as a low brain penetration (CNS-) compound [9]. Both
compounds were reported to show the expected CNS penetration trend when screened
by using IAM phosphatidylcholine column chromatography [11].
2.1.2.3. Determination of the IAM partition coefficients
Samples were prepared by dissolution in absolute ethanol with concentrations of 20
µg/µl, and the IAM partition coefficients were calculated using equations from
literature [11]. KIAM, the IAM capacity factor, was calculated from the following
equation:
6

k IAM

 t − t0 

=  r
 t0


Where tr is the retention time of the drug and t0 is the holdup time of the column. The
permeability of a drug through the BBB by passive diffusion (Pm) is expressed
following correction by the molecular weight of the drug, KIAM /MWn [11]. It was
reported that the most successful differentiation was obtained when the power function
of KIAM /MWn was set at n = 4 at pH 5.5 [11].
2.1.3. In Vivo Validation Using Mass Spectrometry
2.1.3.1. Animals and Dosing
C57BL/6 mice weighing between 25–30 g and Hartley guinea pigs weighing between
900-1000 g were obtained from Charles River Laboratories (Wilmington, MA, USA).
Animal experiments were carried out according to the Institutional Animal Care and
Use Committee (IACUC) guidelines for the care and use of laboratory animals.
Guinea pigs were grouped and anaesthetized with 20% isoflurane/PEG (v/v). One
group was then injected with 200µl of 100 mg/kg tolfenamic acid (n=3), while the
other group was administered 200µl vehicle (n=2) intravenously through the
saphenous vein by the university Attending Veterinarian (AV). The animals were
euthanized within 5-10 minutes, decapitated and their brains were collected and stored
at -80oC. For LC/MS studies, mice were anaesthetized with 20% isoflurane/PEG (v/v)
then injected either with 20µl of 100 mg/kg tolfenamic acid (n=3) or with vehicle
(n=1) into the lateral tail vein by the AV. After 5 minutes, mice were anaesthetized
and euthanized by exsanguination through cardiac puncture. Blood was collected into
7

7.5 units/ml heparin solution-treated tubes. Blood samples were then centrifuged at
1700 x g for 10 minutes and plasma was collected and stored at -80oC. Brain tissue
was extracted and stored in the -80oC freezer.
2.1.3.2. Extraction Procedure and Sample Preparation
A previously published extraction process was followed [15] and 20µl of the extract
was injected into the mass spectrometry (MS) system. An alternate extraction method
was also applied for brain homogenate, plasma and calibration standard samples
analyzed by LC/MS. Each sample was treated with 4:1 0.25 M HCl to sample volume
followed by addition of 50µl of 10 µg/ml diclofenac sodium, the internal standard
(IS). Samples were vortexed for 1 minute followed by the addition of 2 ml ethyl
acetate. After mixing for another minute, samples were centrifuged at 2800 x g for 10
minutes. The organic layer was collected and evaporated to dryness under nitrogen
stream. The residue was reconstituted in 250µl acetonitrile and filtered, then 20µl of
each sample was injected in the LC/MS system for separation. Using a stock solution
of 500 µg/ml tolfenamic acid in acetonitrile, brain samples were spiked with 50µl of
10 µg/ml diclofenac sodium and with tolfenamic acid to produce the final
concentrations of 0.05, 0.1, 0.25, 0.5, 1, 5, 10, 25 and 50 µg/ml tolfenamic acid.
Plasma samples were spiked with 50µl of 10 µg/ml diclofenac sodium and with
tolfenamic acid to produce the final concentrations of 1, 5, 10, 25, 50, 100 and 150
µg/ml tolfenamic acid.
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2.1.3.3. Apparatus and Chromatographic Conditions
MS: Applied Biosystems Mariner® system was used which consisted of an orthogonal
time-of-flight (TOF) mass spectrometer equipped with standard electrospray
ionization (ESI), PE SCIECX’s Turbo Ion Spray™ (TIS) and Atmospheric Pressure
Chemical Ionization (APCI) source. The instrument was outfitted with an integrated
syringe pump with dual syringe rack for direct infusion into the mass spectrometer.
Extracted samples and standards were injected directly at a flow rate of 20 µl/min and
the negative ion mode was used for ion peak detection.
LC-MS Method: LC unit used was an Agilent 1100 series HPLC (Agilent
Technologies, Santa Clara, CA, USA) and separation was performed using Luna
pentafluorophenyl propyl, PFP(2), 50 x 2.0 mm column with a 3 µm particle size
(Phenomenex, Torrance, CA, USA). The Mobile phase used consisted of a mixture of
water with 0.1% formic acid (v/v) (A) and acetonitrile with 0.1% formic acid (v/v)
(B). Gradient elution was employed as follow: 0-15 min, 100% eluent A; 15-30 min,
100% to 0% eluent A; 30-35 min, 100% eluent B; 35-45 min 100% to 0% eluent B;
45-55 min 100% eluent A under a flow rate of 0.2 ml/min. Mass spectroscopy
equipment used was QSTAR® Elite Hybrid LC/MS equipped with a high performance
quadruple time of flight (QqTOF) mass spectrometer, a turbo ion spray, and Analyst®
QS 2.0 software. For each sample, 20µl was injected and MS detection was conducted
using the negative ion mode.

9

3.

Results

3.1. In Silico Computational Brain Transfer Prediction of Tolfenamic Acid
LogBB values for tolfenamic acid and some adrenergic blockers including
propranolol, timolol and atenolol were calculated (Table 1) using Clark’s equation
[16]. Compounds that have logBB value of > 0.3 distribute freely to the brain
however, compounds of logBB value of < -1 distribute poorly to the brain [17]. The
logBB for tolfenamic acid was calculated to be 0.75 predicting its ability to distribute
well into the brain. Propranolol had a calculated logBB of 0.1 that was less than the
cutoff value to cross freely into the brain (0.3). However, it was much higher than -1,
the reported value of which less than that a compound is predicted to be of poor CNS
penetration. The calculated logBB for timolol and atenolol, both of which have poor
CNS penetration as documented in the literature [9, 10], were -0.9 and -1.0,
respectively, indicating their low ability to distribute into the brain.
Another index of BBB permeability, LogPS, was obtained for tolfenamic acid and the
three antiadrenergic drugs (Table 1) using ACD/ADME Suite software [14]. The
program predicts compounds with logPS values less than -5 to be unable to transfer
into the brain. The calculated LogPS values for tolfenamic acid and propranolol were 2.1 and -2 respectively and thus both are predicted to transfer into the brain. The
values of logPS for timolol and atenolol were -3 and -3.9 respectively which were
close to the cutoff value of -5.0 for drugs that are predicted not to transfer into the
brain.

10

Tolfenamic acid values of other brain transfer descriptors including octanol-water
partition coefficient (logP), molecular weight, free rotatable bonds (FRB), hydrogenbond donor/acceptor number (Hd and Ha) and polar surface area (PSA) were consistent
with the optimum values for drugs that distribute into the brain (Table 1). LogP is an
indicator of lipophilicity; the higher the number the higher the lipophilicity. Predicted
LogP for tolfenamic acid was 5.86 indicating it can passively cross the BBB. The
molecular weight of tolfenamic acid is 261.7 Da which is less than 450 Da, a
requirement for brain penetration [18]. Tolfenamic acid’s predicted FRB was 3 and
compounds with FRB >7 are considered of low BBB permeability [16]. Compounds
that permeate into the CNS usually have 0-4 hydrogen-bond donors and 1-5 hydrogenbond acceptors [19] and the drug has two hydrogen-bond donors and three hydrogenbond acceptors. The PSA value for tolfenamic acid was predicted to be 49.3 Å2 and
for brain penetration, the PSA should be <90 Å2 [18]. Thus, the predicted values of
logBB, logPS and other brain transfer descriptors strongly suggest that tolfenamic acid
would passively distribute into the brain to a great extent.
3.2. In vitro Brain Transfer Prediction of Tolfenamic Acid
Using the IAM phosphotidylcholine column chromatography method described by
Yoon et al, (2006) [11], the (KIAM/MW4) x1010 values at pH 5.5 for tolfenamic acid
and the reference compounds, propranolol and timolol, were obtained (Table 2).
Compounds with IAM capacity factors (KIAM/MW4)x1010 > 1.01 have high CNS
penetration while compounds with (KIAM/MW4)x1010 < 0.64 values have low CNS
penetration [11]. Although we had higher IAM capacity factor values than reported by
11

Yoon et al. for propranolol and timolol, the order of the values was consistent. The
classification of CNS penetration of tolfenamic acid, propranolol and timolol based on
their IAM capacity factor values was determined (Fig. 1). With a (KIAM/MW4)x1010
value of 2.73, our in vitro prediction model indicated the ability of tolfenamic acid to
transfer into the CNS.
3.3. Presence of Tolfenamic Acid in the Brains of Guinea Pigs after IV
Administration
Mass spectra data of tolfenamic acid presence in the brain after intravenous
administration in guinea pigs were the first evidence of the ability of tolfenamic acid
to have brain disposition criteria (Fig. 2). These data suggest that tolfenamic acid’s
presence in the brain following IV administration validates our computation and in
vitro prediction results; however, we still need to obtain the evidence of this

disposition of tolfenamic acid in the brain relative to the plasma concentration and
such relativity is expressed as the brain-to-plasma ratio of tolfenamic acid.
3.4. Determination of Brain-to-Plasma Concentration Ratio of Tolfenamic Acid
Using the LC-MS method, the brain-to-plasma concentration ratio of a single timepoint, Kp, was determined after intravenous administration of 20µl of 100 mg/kg
tolfenamic acid to mice via their lateral vein. Tolfenamic acid peak was identified in
the brain (Fig. 3), confirming the earlier results of tolfenamic acid detection after IV
administration into guinea pigs, as well as in the plasma (Fig. 4). The areas under the
tolfenamic acid peaks in the brain and plasma were plotted versus the standard
calibration curves of brain and plasma and were quantified using the quantification
12

wizard Analyst® QS 2.0 software. The concentration of tolfenamic acid in the brain
was 1.21 µg/g whereas the measured concentration of tolfenamic acid in the blood was
10.85 µg/ml and thus the Kp value calculated after 5 minutes following IV
administration was 0.11.
4.

Discussion

The delivery of therapeutic agents to the CNS is of great importance in CNS drug
discovery. The BBB prevents many drugs from accessing the CNS, and hence poses a
significant challenge for drug delivery into the CNS [20]. A survey of the
Comprehensive Medicinal Chemistry (CMC) database showed that only 5% of over
7,000 drugs listed were CNS active [21]. Presently, several methods are available to
assess the potential of candidate drugs to penetrate the BBB including in silico, in
vitro and in vivo approaches. We applied these approaches comparatively in

assessment of the ability of tolfenamic acid to cross the BBB as a drug that we have
demonstrated experimentally that it affects processes associated with amyloidogenesis
in the brain [1].
Computational approach, compared to in vitro and in vivo methods, is cost effective
and requires less time for analysis in brain penetration studies, however, the
performance of such a model depends on the data input, descriptor used and modeling
approaches [7]. The calculated

LogBB value for tolfenamic acid using

ACD/ChemSketch 12.0 software [12] showed its ability to cross the BBB and this
prediction was consistent with its physicochemical properties (Table 1). With some
controversy about the validity of using logBB as indicator of brain penetration [22],
13

ACD/ADME Suite software [14] was used to predict brain penetration by analyzing
logPS value which also indicated the ability of tolfenamic acid to cross into the CNS.
The predicted logBB of propranolol (0.1) was much less than the actual experimental
value (1.57) which can be explained by the presence of active transport mechanisms
that deliver propranolol into the brain [8]. A limitation of computational models is that
they can only predict brain penetration as a function of passive permeability and do
not consider other factors such as efflux and influx transporters and plasma protein
binding which can affect brain transfer of drugs. With limited number of compounds
to design logBB and logPS models and the fact that experimental logBB and logPS
were generated from different protocols, the computational prediction can sometimes
be contradictory and uncertain [7]. Thus, we advanced into comparing our
computational results with an in vitro model.
In vitro models to determine brain penetration are developed in a way to mimic in vivo

brain penetration, hence, there are various in vitro cell-based and non-cell-based
models [7]. IAM chromatography technique has been experimented to predict BBB
permeability [11, 23] with less complexity compared to other cell based models that
require cell culture cycles. Using this method, our results showed that tolfenamic acid
had a kIAM that reflected its ability to permeate through the BBB. The obtained kIAM
value for tolfenamic acid was intermediate between that of propranolol and timolol.
While it was not close to that of propranolol, it was much higher than that for timolol,
thus we concluded that tolfenamic acid was CNS+ and that its ability to penetrate the
brain was intermediate in nature. Although IAM chromatography is a rapid and simple
14

method which provides a promising tool for assessing BBB permeability, it has few
limitations which include the fact that lipid molecular dynamics including lateral
diffusion are not mimicked by IAM and that BBB permeation prediction becomes
unreliable by IAM if the drug brain uptake is influenced by transporters or plasma
protein binding [7, 11, 23]. However, there are numerous cellular systems that can be
used to evaluate the influence of BBB efflux transporters including P-glycoprotein
(PGP) and multi-drug resistant proteins (MRP) on CNS distribution of drugs. For
examples, human colon adenocarcinoma (Caco-2) and MDR1-trasfectted MadinDarby Canine Kidney (MDCK) cell lines have been good tools for evaluating the BBB
efflux transporters effect on different compounds [7]. Nevertheless, some limitations
of using such models are valid. The fact that the in vivo BBB contains other efflux
transporters which could exert a major effect in the overall BBB penetration and the
fact that MDCK cell line also expresses the organic cation transporter (OCT-2) could
lead to complications when interpreting generated data [7, 24]. Thus, the in vitro
findings, inevitably, needed to be validated in vivo.
Several invasive and noninvasive in vivo methods are designed for brain uptake
experiments, which represent the most reliable validation of other models [7, 25].
Tolfenamic acid was present in the brain after intravenous administration in guinea
pigs as detected by MS (Fig. 2). However, as already mentioned, we still need to
obtain the evidence of this disposition of tolfenamic acid in the brain relative to the
plasma concentration and such relativity is expressed as the brain-to-plasma ratio of
tolfenamic acid.
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The plasma-to-brain concentration ratio, the most widely used term for evaluating
brain penetration [26], was assessed for tolfenamic acid after 5 minutes and was
calculated to be 0.11 indicating its disposition into the brain in low levels that might
be due to the early time point chosen. With no pharmacokinetic (PK) data available
regarding the disposition of tolfenamic acid through the mouse body, multiple timepoint assessment and determination of area under the curve (AUC) concentration in
brain and plasma is needed for more accurate experimental calculations of the drug
PK. Also, Kp is heavily affected by the binding of the drug in brain and plasma [26]
and it is known that tolfenamic acid has a very high plasma binding level up to 99.7%
in human [27] and this could explain well the low Kp total. Thus, to avoid the effect of
the non-specific binding, determination of the free unbound drug levels in the brain
and plasma to generate the unbound brain-to-plasma concentration ratio, Kp,uu, could
provide a better analysis of the brain penetration of tolfenamic acid. In addition, Kp,uu
could describe the effect of efflux and influx transporters at the BBB on the CNS
distribution of tolfenamic acid, if any.
To conclude, comparative analysis of multiple approaches has predicted and validated
the ability of tolfenamic acid to penetrate into the CNS and exert its effects that are
manifested in lowering amyloidogenesis and treatment of migraine.
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Table I-1. LogBB and logPS values obtained using in silico computational
prediction software with related parameters for tolfenamic acid, propranolol,
timolol and atenolol.
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a

Molecular weight in Dalton; b Polar Surface Area; c The number of hydrogen-bond donors; d The
number of hydrogen-bond acceptors; e Free rotatable bond; g Octanol-water partition coefficient; h
Equilibrium distribution between blood and brain; i Passive permeability-surface area product; j
Equation for calculating logBB which was extracted by analyzing logBB values of a database of 179
data points measured in rats which showed that logBB determination is strongly dependent on logP,
PSA and FRB [16].
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Table I-2. Human CNS penetration evaluation of propranolol, timolol and
tolfenamic acid from literature and calculated from the Immobilized Artificial
Membrane

(IAM)

capacity

factor

Chromatography [11].
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[(KIAM/MW4)x1010]

using

IAM

Compound

CNS Penetrationa (KIAM/MW4)x1010 CNS Penetrationb

Propranolol

CNS+

6.16

CNS+

Timolol

CNS-

0.73

CNS-

Tolfenamic Acid

-

2.73

CNS+

a

CNS penetration obtained from literature [8, 9]; b CNS penetration based on (KIAM/MW4)x1010
values at pH 5.5; CNS+ (KIAM/MW4)x1010 > 1.01, CNS- (KIAM/MW4)x1010 < 0.64 [11].
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Figure I-1. Classification of CNS penetration of tolfenamic acid, propranolol and
timolol using IAM chromatography. The IAM capacity factor [(KIAM/MW4)x1010]
at pH 5.5 was determined. High BBB penetration (CNS+); (KIAM/MW4)x1010 > 1.01,
low BBB penetration (CNS-); (KIAM/MW4)x1010 < 0.64, Uncertain BBB penetration;
(KIAM/MW4)x1010 = 0.65-1.
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Figure I-2. Mass spectra analysis of tolfenamic acid in the brain of guinea pigs
following intravenous administration. Tolfenamic acid was administered through
the saphenous vein (200µl of a 100 mg/kg dose) and its levels were analyzed. Ovals
denote the desired tolfenamic acid peak with m/z of 259.8. (a) Tolfenamic acid
standard in ethanol (1 mg/ml); (b) Brain extract from vehicle dosed animals; (c) Brain
extract from tolfenamic acid dosed animals; (d) Extracted tolfenamic acid peak from
mass spectrum(c).
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Figure I-3. Extracted ion count chromatogram of tolfenamic acid in the brain of
mice following intravenous administration. Tolfenamic acid was administered
through the lateral tail vein (20µl of a 100 mg/kg dose) and its levels in the brain were
analyzed using the extraction and LC-MS methods described in the methods section.
The area under tolfenamic acid peak was used for brain-to-plasma concentration ratio
calculation. TA = Tolfenamic acid; IS = Internal standard (diclofenac sodium).
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Figure I-4. Extracted ion count chromatogram of tolfenamic acid in the plasma
of mice following intravenous administration. Tolfenamic acid was administered
through the lateral tail vein (20µl of a 100 mg/kg dose) and its levels in the plasma
were analyzed using the extraction and LC-MS methods described in the methods
section. The area under tolfenamic acid peak was used for brain-to-plasma
concentration ratio calculation. TA = Tolfenamic acid; IS = Internal standard
(diclofenac sodium).
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Reversal of Cognitive Deficits by Tolfenamic Acid is Accompanied by Reductions
in Intermediates Associated with Amyloid Pathology in a Transgenic Mouse
Model of Alzheimer’s Disease
By
Gehad M. Subaiea, Lina I. Adwan, Aseef H. Ahmed and Nasser H. Zawia
(Intended publication in Neurobiology of Aging)
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Abstract
Data from our lab had shown that tolfenamic acid lowers the levels of the amyloid
precursor protein (APP) and amyloid beta (Aβ) peptide when administered to
C57BL/6 mice by lowering the levels of their transcriptional regulator specificity
protein 1 (Sp1). In this study, we examined the ability of tolfenamic acid to improve
the cognitive deficits in a transgenic mouse model of Alzheimer’s disease (AD),
R1.40, as well as to reduce the expression of genes and the levels of proteins
associated with AD, including SP1, APP and Aβ. Following characterization of the
ensuing cognitive deficits in aged hemizygous R1.40 transgenic mice, we
administered variable doses of tolfenamic acid or vehicle for thirty four days.
Behavioral assessment of spatial learning and memory functions began on Day 15
using the Morris water maze. Working memory was tested using the Y-maze. Results
showed that tolfenamic acid improved both long-term spatial memory deficits as well
as working memory in these mice. These improvements were accompanied by
reductions in the levels of the transcriptional activator SP1, followed by decreases in
both the mRNA and protein levels of APP, and subsequent Aβ levels. These findings
provide evidence of the ability of tolfenamic acid to disrupt the development and the
progression of the pathological processes associated with AD, manifested by the
reduction of amyloidogenic proteins, and amelioration of cognitive dysfunctions.

Keywords: Alzheimer’s disease; tolfenamic acid; AD transgenic mouse model;
learning and memory; Morris water maze; Y-maze.
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1. Introduction
Alzheimer’s disease (AD) represents the most prevalent neurodegenerative diseases in
the elderly. During the course of the disease, memory, cognitive performance, and
other daily activities are all impaired as a result of extensive neuronal loss (Berg, et
al., 1993; Braak and Braak, 1997; Nelson, et al., 2012). AD is characterized by the
presence of neuropathological deposits consisting of extracellular senile plaques of βamyloid core and intraneuronal neurofibrillary tangles (NFTs) in different brain
regions, especially in the cerebral cortex, hippocampus, subcortical nuclei and
amygdala (Selkoe, 2001; Reddy, et al., 2010; Ballard, et al., 2011; Harrington, 2012).
The amyloid precursor protein (APP) is processed by beta-site APP-cleaving enzyme
1 (BACE1) and γ-secretase proteases to generate various β-amyloid (Aβ) peptide
isoforms that can accumulate resulting in the formation of insoluble aggregates of
amyloid plaques (Shoji, et al., 1992; Urbanc, et al., 1999; Querfurth and LaFerla,
2010; Zhang, et al., 2012). Aβ1-40 and Aβ1-42 are the major generated isoforms with
Aβ1-42 found to be more aggregative triggering amyloid plaque formation (Finder and
Glockshuber, 2007). Accumulation of Aβ into amyloid plaques initiates a pathological
cascade resulting in synaptic dysfunction and neuronal death that contribute to the
neurodegeneration observed in AD according to the amyloid hypothesis (Hardy and
Higgins, 1992; Selkoe, 2001).
Over the last two decades, more evidence has been garnered as to the association
between chronic NSAIDs intake and up to 80% reduction in risk of AD incidence,
slowing of disease progression, and reduction of microglial activation (Andersen, et
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al., 1995; McGeer, et al., 1996; Stewart, et al., 1997; in t' Veld, et al., 2001; Lindsay,
et al., 2002; Zandi, et al., 2002; Etminan, et al., 2003; Vlad, et al., 2008; Cote, et al.,
2012). However, several prospective clinical trials failed to demonstrate the efficacy
of NSAIDs in altering AD risk (in 't Veld, et al., 1998; Hayden, et al., 2007; Lyketsos,
et al., 2007; Arvanitakis, et al., 2008). Nonetheless, the findings of the ability of a
subset of NSAIDs to alter AD pathology and improve cognitive performance in
murine mouse models of AD by mechanisms other than their classic cyclooxygenase
(COX) inhibition have led to a renewed interest in these compounds as potential
disease-modifying agents in AD (Weggen, et al., 2001; Zhou, et al., 2003; Lleo, et al.,
2004).
No cure has been discovered for AD yet and FDA-approved drugs for use in AD
include four cholinesterase inhibitors and one N-methyl-D-aspartate receptor
antagonist. However, these medications are not disease-modifying therapies and they
do not stop the progression of the disease (Ozudogru and Lippa, 2012). Current
research focuses on interventions that target Aβ production and aggregation, and the
production of hyperphosphorylated tau (Gotz, et al., 2012; Ozudogru and Lippa,
2012); however, no therapeutic strategy has explored more upstream interventions at
the transcriptional level. Specifitcity protein 1 (Sp1) co-activates the transcription of
APP, BACE1 and tau genes (Heicklen-Klein and Ginzburg, 2000; Christensen, et al.,
2004; Docagne, et al., 2004). Consequently, changes in its levels can alter the
downstream pathways related to amyloidogenesis (Basha, et al., 2005; Adwan, et al.,
2011) and tau (unpublished data) pathology representing an ideal target for a disease36

modifying intervention. Tolfenamic acid, a non-steroidal anti-inflammatory drug
(NSAID), induces the degradation of SP1 protein (Abdelrahim, et al., 2006) and data
from our lab have shown that the treatment of wild type C57BL/6 mice with
tolfenamic acid lowers the levels of SP1 and the expression of AD-related Sp1 target
genes such as APP (Adwan, et al., 2011). Unpublished data from our lab also indicate
that it can do the same to both BACE1 and tau.
Transgenic mouse models of AD represent useful tools for elaborating mechanisms
involved in the development and progression of AD. In addition, they allow for
testing of new therapies in vivo to provide more accurate data to justify testing in
human clinical trials (Hock and Lamb, 2001; Duff and Suleman, 2004). Thus, we
decided to examine the ability of tolfenamic acid to lower AD proteins, including
SP1, APP, and Aβ, and to examine whether such reductions are commensurate with
an improvement in cognitive functions in a mouse model of AD. Since the
endogenous APP promoter is largely driven by Sp1 (Docagne, et al., 2004), we
chose to study the effects of tolfenamic acid, which degrades SP1, in R1.40 mouse
model which utilizes the human APP promoter.
Thus, the purpose of this experiment was to investigate the presence of memory
deficits in the hemizygous R1.40 mice, a genomic-base transgenic mouse model that
harbor the Swedish mutation APPK670N/M671L (Lamb, et al., 1993), and to
examine the ability of tolfenamic acid to attenuate such deficits and to decrease ADrelated pathology. Therefore, following characterization of the learning and memory
impairment in female hemizygous R1.40 transgenic mice, 5 and 50 mg/kg/day
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tolfenamic acid was administered to female R1.40 mice aging between 14-21
months via oral gavage for 34 days and the learning and memory functions were
assessed in the Morris water maze and the Y-maze. On Day 35, mice were
euthanized and AD associated proteins including SP1, APP and soluble and
insoluble Aβ1–40 and Aβ1–42 were assessed in the frontal cortex, which displays
extensive AD pathology in this animal model (Kulnane and Lamb, 2001; Lehman, et
al., 2003).
2. Methods
2.1. Animal model

The transgenic mouse model R1.40 was utilized for this study. These transgenic mice,
B6.129-Tg(APPSw)40btla/J, were obtained from the Jackson laboratory (Bar Harbor,
ME, USA) and colonies of hemizygous and homozygous strains were established inhouse. R1.40 is a genomic-based transgenic mouse model that was developed by
Bruce T. Lamb, and it utilizes a yeast artificial chromosome (YAC) that contains the
full 400 kb human APP gene and flanking sequence of approximately 250 kb to harbor
the Swedish mutation APPK670N/M671L including the human transcriptional
regulatory elements needed for proper spatial and temporal expression (Reaume, et al.,
1996; Lamb, et al., 1997; Hock and Lamb, 2001). The developed hemizygous R1.40
line shows a great increase in APP and Aβ production as early as 6 months of age with
Aβ plaque deposition occurring at 24-26 months of age compared to the wild type
mice and it was concluded that the mnemonic deficits in R1.40 were similar to those
observed in AD (Lamb, et al., 1999; Hock, et al., 2009).
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2.2. Genotyping of R1.40 transgenic mice

In order to establish transgenic mice colonies of hemizygous and homozygous R1.40,
mice were bred and genotyped in-house at the University of Rhode Island. To ensure
the accuracy of genotyping results, two genotyping techniques were performed:
standard PCR followed by gel electrophoresis on 1.5% agarose gel, and the TaqMan®
allelic discrimination assay (Applied Biosystems, Foster City, CA, USA). The
breeding and genotyping methods were approved by University of Rhode Island
Institutional Animal Care and Use Committee (IACUC).
2.2.1. DNA isolation

DNA was isolated from mouse tissue as described in the literature (Truett, et al.,
2000). In brief, tissue was obtained through tail snipping (2 mm) and was placed in
Eppendorf tubes followed by adding 75µl of a mix of 25 mM sodium hydroxide
(NaOH) and 0.2 mM ethylenediaminetetraacetic acid (EDTA). The tubes were placed
in a thermocycler (Bio-Rad, Hercules, CA, USA) at 98°C for 1 hr followed by cooling
at 15 ºC. After that, 75µl of 40 mM Tris hydrochloride (HCl) of pH 5.5 was added and
mixed. Tubes were centrifuged at 1700 × g for three minutes and supernatants were
collected. DNA concentration and quality was checked using the NanoDrop 2000
Micro-Volume UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE,
USA).
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2.2.2. Standard PCR and agarose gel electrophoresis

Standard PCR genotyping method for R1.40 mice was performed as provided by the
Jackson laboratory (Bar Harbor, ME, USA). The primer pairs for the APP transgene
used were: IMR6938 (5'-CTT CAC TCG TTC TCA TTC TCT TCC A-3') and
IMR6939 (5'-GCG TTT TTA TCC GCA TTT CGT TTT T-3'). Each reaction
consisted of a mixture of 10µl TaqMan® genotyping master mix (Applied Biosystems,
Foster City, CA, USA), 2µl of each primer and 2µl DNA from test samples. PCR
amplification step was performed using a thermocycler (Bio-Rad, Hercules, CA, USA)
as follows: 94°C for 3 min and then 35 cycles of 94°C for 30 sec, 65°C for 30 sec and
72°C for 30 sec, and then at 72°C for 2 min. Bands were then separated by gel
electrophoresis on 1.5% agarose gels containing ethidium bromide and bands were
visualized using Typhoon™ 9410 Variable Mode Imager (GE Healthcare, Piscataway,
NJ, USA).
2.2.3. TaqMan® allelic discrimination assay

To distinguish between hemizyougs and homozygous R1.40 YAC APP and WT,
TaqMan® allelic discrimination assay was performed. SNP genotyping assay,
catalogue: M_23312848_20, containing the context sequence ([VIC/FAM]): TAC
TGC TCA CTC TTT TAA CAA ACA T[A/G]G GAA ACT AAT GAA ATG GTA
TCA CAA was obtained from ABI (Applied Biosystems, Carlsbad, CA, USA) and the
assay was performed according to ABI protocol. Briefly, each reaction consisted of
6.25µl 2× TaqMan® genotyping master mix (Applied Biosystems, Foster City, CA,
USA), 0.625µl 20× SNP genotyping assay mix, 3.125µl RNase free water and 2.5µl
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genomic DNA from test samples. The pre-read run and PCR amplification were
conducted in a 7500 Real-Time PCR System following ABI standard protocol, which
was 95°C for 10 min followed by 40 cycles of 92°C for 15 sec and 60°C for 1 min.
Following the post-read run, results were analyzed using the sequence detection
software (SDS, version 1.3) from ABI and the allelic discrimination scatter plots were
automatically generated.
2.3. Assessment of cognitive deficits in hemizygous R1.40 transgenic mice

In order to characterize memory and cognitive deficits in the hemizygous R1.40
transgenic mouse model, behavioral testing in mazes that are dependent on the
integrity of the hippocampus and brain cortex was conducted using the Morris water
maze and spontaneous alternations in the Y-maze. Female hemizygous APP transgenic
(n=19) and female control wild type (n=18) groups of ages ranging between 9-20
months were used.
2.3.1. Morris water maze

We have tested the mice in the hidden version of the Morris water maze. In this task,
the mice had to locate the hidden platform by learning multiple spatial relationships
between the platform and the distal extra-maze cues (Vorhees and Williams, 2006;
Gulinello, et al., 2009; Laczo, et al., 2009). The apparatus consisted of a white 48”
diameter pool that is 30” in height and was filled with water to a depth of 14”. The
water was kept opaque by the addition of white non-toxic liquid washable paint. The
pool was surrounded by distinct fixed visual cues that the animals used to navigate
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to reach the escape platform. A clear Plexiglas platform square of 10 cm was kept
submerged 0.5 cm below the surface of the water. The temperature of the water was
kept 25 ±2°C during all procedures in the water maze. On Day 15 of tolfenamic acid
administration, mice received a habituation trial in which they were allowed to swim
freely for 60 sec. On the following day and for a total of 8 days, mice received
training sessions of 3 trials daily. The starting position for each trial was randomly
assigned between the four possible positions while the platform position was fixed
in each trial. Each animal was allowed to swim until they found the immersed
hidden platform or for a maximum duration of 60 sec. If the mouse failed to locate
the platform, it would be gently guided to sit on the platform for a maximum
duration of 30 sec. Mice were also left to sit on the platform for a maximum of 10
sec upon successful trial. Upon conducting the 8 acquisition sessions, probe trials for
up to 60 sec on Day 1 and Day 11 following the last day of training were performed
to assess the long term memory retention by studying the preference of the mice for
the correct quadrant that previously contained the hidden platform. The swim paths
and latencies to locate the platform were videotaped and tracked with a
computerized video tracking system (ObjectScan, Clever Sys. Inc., Reston, VA,
USA) and the resultant data were analyzed.
2.3.2. Spontaneous alternations in the Y-maze

The spontaneous alternation ratio, defined as the percentage of the number of arm
entries, different from the previous two entries, divided by the total arm entries
minus two (King, et al., 1999; Hock, et al., 2009) was measured. Testing was
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conducted in a white Y-maze with arms that were 12” (long) by 3” (wide) with 8”
height walls. Mice were placed into one of the Y-maze arms and were left to explore
the maze freely for 5 minutes. After each trial, the maze was cleaned with 70%
ethanol. Y-maze trials were videotaped and tracked with a computerized video
tracking system (ObjectScan, Clever Sys. Inc., Reston, VA, USA) and the data were
analyzed.
2.4. Animal exposure to tolfenamic acid and behavioral testing

Tolfenamic acid was obtained from Sigma Aldrich (St. Louis, MO, USA) and female
hemizygous APP YAC transgenic mice aging between 14-21 months were used to
examine the ability of tolfenamic acid to reduce the amyloidogenic load and to
improve the learning and memory deficits of the mice. The animals were divided into
three groups of similar age variation and were administered tolfenamic acid daily via
oral gavage for 34 days; one group was administered 5 mg/kg/day tolfenamic acid in
corn oil (n=6); the second group was administered 50 mg/kg/day tolfenamic acid in
corn oil (n=7) and the third group was administered corn oil, the vehicle, (n=6). After
14 days of daily dosing, mice were tested in the Morris water maze as described in
section 2.3.1. On Day 33, mice were tested for spontaneous alternations in Y-maze as
described in section 2.3.2. Finally, on Day 35, mice were euthanized and brain tissue
was extracted, dissected and stored at -80°C. Figure 1 provides a timeline for the
experimental events involved in this study of drug administration and behavioral
assessment.
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2.5. Protein extraction and Western blot analysis

Brain cortices were homogenized with RIPA lysis buffer containing 10 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, and 0.1%
protease inhibitor cocktail. The homogenates were centrifuged at 10,000 × g for 10
minutes at 4°C and supernatants were collected. Protein levels were determined using
the BCA kit (Pierce Biotechnology Inc., Rockford, IL, USA). Forty µg of total protein
was separated on 8% SDS polyacrylamide gel and then transferred onto
polyvinylidiene diflouride (PVDF) membranes (GE Healthcare, Piscataway, NJ,
USA). Membranes were blocked using 5% non-fat milk in TBST (Tris buffered saline
+ 0.5% Tween-20, pH 7.4) for 1 hr. After that, membranes were incubated overnight
at 4°C with the specific antibody diluted in TBST for 1 hr (1:2000 dilution of 6E10 for
APP (Covance Research Products Inc., Dedham, MA, USA) and 1:500 dilution of 1C6
for SP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing
membranes 4 times with TBST, membranes were incubated for one hour with the
appropriate anti-mouse IRDye® 680 (Li-Cor Bioscience, Lincoln, NE, USA) (1:5000)
at room temperature. After washing the membranes twice with TBST, the images were
developed using the Li-Cor Odyssey infrared imaging system (Li-Cor Bioscience,
Lincoln, NE, USA). The membranes were also re-probed for β-actin (Sigma Aldrich,
St. Louis, MO, USA) at a dilution of 1:2500 in TBST to obtain the APP/β-Actin ratio.
The intensities of the obtained Western blot bands were determined using Odyssey
V1.2 software (Li-Cor Bioscience, Lincoln, NE, USA).
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2.6. RNA isolation, synthesis of cDNA and quantitative Real-Time PCR

RNA was isolated from cortical tissue following the TRIzol® Reagent method
(Invitrogen, Carlsbad, CA, USA), checked for integrity using NanoDrop 2000 MicroVolume UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and
gel electrophoresis. RNA was reverse transcribed to cDNA using the iScriptTM Select
cDNA Synthesis Kit following manufacturer’s instructions (Bio-Rad, Hercules, CA,
USA). About 1000ng of RNA was diluted to 19.5µl with nuclease free water, then 3µl
Oligo (dT) mix, 6µl 5x iScript Select reaction mix, and 1.5µl of iScript reverse
transcriptase was added. Samples were incubated at 42°C for 90 min then at 85°C for
5 min to terminate the reaction. All incubations were conducted using MJ Research
MiniCyclerTM PTC-150 (Bio-Rad, Hercules, CA, USA). Primer pairs for Sp1, APP
and β-actin were obtained from Invitrogen (Carlsbad, CA, USA) as follows: Sp1
sense: 5’-CAA GCC CAA ACA ATC ACC TT-3’, and antisense, 5’-CAA TGG GTG
TGA GAG TGG TG-3’; APP sense: 5’-TGC AGC AGA ACG GAT ATG AG-3’, and
antisense: 5’-ACA CCG ATG GGT AGT GAA GC-3’; β-actin sense: 5’-TGT TAC
CAA CTG GGA CGA CA-3’, and antisense: 5’-TCT CAG CTG TGG TGG TGA
AG-3’. Each Real-Time PCR reaction mix contained 2µl of cDNA, 1µl of each
primer, 8.5µl nuclease free water and 12.5µl SYBR® Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). Real-Time PCR was conducted using 7500 RealTime PCR System (Applied Biosystems, Foster City, CA, USA) following the
standard protocol: 50°C for 2 min followed by 95°C for 10 min, then 40 cycles of
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95°C for 15 sec and 60°C for 1 min. Results were analyzed using SDS software and
expression data were reported relative to β-actin mRNA using the 2-∆∆Ct method.
2.7. ELISA Aβ1–40 and Aβ1–42 assay

Amyloid beta (Aβ) levels both soluble and insoluble fractions were determined by
enzyme-linked immunosorbent assay (ELISA) using human Aβ1–40 and Aβ1–42 assay
IBL kits JP27713 and JP27711 (Immuno-Biological Laboratories, Gunma, Japan).
These kits are solid-phase sandwich ELISA with two types of highly specific
antibodies that are 100% reactive with mouse Aβ1-40 with a sensitivity of 5.00 pg/mL
(JP27713), and 70% reactive with mouse Aβ1-42 with 4.03 pg/mL sensitivity
(JP27711). The assay conditions were followed according to a method described in the
literature (Morishima-Kawashima, et al., 2000) with slight modifications. Brain tissue
was homogenized in Tris-saline (TS) [50 mM Tris-HCl buffer, pH 7.4, 150 mM NaCl,
1 µg/ml TLCK (N-α-p-tosyl-L-lysine chloromethyl ketone), 1µg/ml antipain, 0.5 mM
DIFP (diisopropyl fluorophosphates), 0.5 mM PMSF, 0.1% protease inhibitor
mixture] and centrifuged at 100,000 × g for 20 min at 4°C. The supernatant was
collected as the soluble fraction of Aβ. The pellet was resuspended in 4 vol of TS and
centrifuged at 70,000 × g for 20 min at 4°C. The resultant pellet was dissolved in
500µl of 6 M guanidine-HCl (in 50mM Tris buffer, pH 7.6), incubated at room
temperature for 30 min, and centrifuged at 70,000 × g for 20 min at 4°C. The resultant
supernatant was collected as the insoluble fraction of Aβ and diluted by enzyme
immunoassay (EIA) buffer (supplied with the kit) to 12× to reduce sample guanidineHCl concentration. Protein levels were determined using the BCA kit (Pierce
46

Biotechnology Inc., Rockford, IL, USA). Aliquots (100µg of protein in 100µl of EIA
buffer) and assay standards were added to 96-well plates [pre-coated with anti-human
Aβ1-40 and Aβ1-42] and were incubated overnight at 4°C. The wells were washed seven
times with EIA buffer. Then, 100µl of labeled antibody was added to each well
containing sample or standard and incubated at 4°C for 1 hr. The wells were washed
nine times with EIA buffer followed by the addition of 100µl of tetramethylbenzidine
(TMB) buffer, and incubated in the dark for 30 min at room temperature. The reaction
was stopped by adding 100µl of 1N H2SO4, and the colorimetric absorption was
measured at 450 nm using Spectra Max UV/Vis Spectrometer (GMI Inc., Ramsey,
MN, USA). The levels of Aβ in the test samples were calculated relative to the
standard curve generated on each plate.
2.8. Statistical analysis

Biochemical data are expressed as the mean ± the standard error of the mean (SEM).
The significance of difference in behavioral performance in the Morris water maze
daily training sessions between the hemizygous R1.40 and the wild type groups was
determined using repeated measure analysis of variance (ANOVA) while probe
trails difference between both groups was determined by two-tailed student t-test.
The significance of difference between different treatment groups was determined
by repeated measure ANOVA and Tukey-Kramer multiple comparison post-hoc
test. All statistical analyses were conducted using GraphPad InStat 3 software
(GraphPad Software, La Jolla, CA, USA). Probability (p) value of <0.05 was
considered statistically significant.
47

3. Results
3.1. Genotyping of R1.40 mice

The primer pairs IMR6938 and IMR6938 amplified the 84 bp PCR product from the
mutant human APP whereas no PCR product was expected from the non-transgenic
mice (Fig. 2A). Thus, the detected bands at 84 bp in agarose gels represent either a
hemizygous or homozygous mutant APP alleles. Allelic discrimination scatter plots
were generated showing three cluster groups classifying the unknown samples as
hemizygous APP mice having both allele A and allele G, and as homozygous APP
mice having allele G or wild type mice having only Allele A (Fig. 2B). Thus, by
allelic discrimination assay we were able to identify hemizygous and homozygous
transgenic APP mice, and the wild type mice as well.
3.2. Hemizygous R1.40 exhibits cognitive impairments when tested in Morris water
maze and in the Y-maze

Spatial navigation in the Morris water maze is one type of the tests used to assess
long-term memory functions, which is usually impaired in AD. In the daily sessions
that consisted of three trials per day for a total of eight days, repeated measure
ANOVA indicated no significant difference in the performance in this task, assessed
by measuring escape latency, between the transgenic group and the control wild type
mice (F(7,245) = 0.924, p ≥ 0.05) (Fig.3A). However, probe trials that assessed the
percent time in the correct quadrant that contained the hidden platform showed that
as the retention delay increased from Day 1 following the last day of the daily
training sessions to Day 11, the transgenic mice exhibited memory impairment as
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they failed to remember the location of the hidden platform. As shown in Fig. 3B,
probe trial in Day 1 following the last day of daily training sessions showed no
significant difference between both groups (p > 0.1). However, after a longer delay
on Day 11 following the last day of daily trainings sessions, the hemizygous R1.40
transgenic mice significantly spent less time (M = 23% ; SEM = 1.99%) compared
to the control wild type mice (M = 29.8% ; SEM= 2.58%), p = 0.045 (Fig. 3B).
Working memory function was assessed by measuring the spontaneous alternations
in the Y-maze defined as the percentage of the number of arm entries, different from
the previous two entries, divided by the total arm entries minus two. This task is
based on the innate nature of the mice to visit arms that have not been recently
visited (King, et al., 1999; Hock, et al., 2009). Results revealed that hemizygous
transgenic R1.40 mice exhibited impaired working memory function as they had a
significantly lower spontaneous alternation ratio (M = 0.413 ; SEM = 0.021) than
the control wild type mice (M = 0.496 ; SEM = 0.019), p = 0.0047 (Fig. 4).
3.3. Treatment with tolfenamic acid reverses the cognitive deficits in hemizygous
R1.40 mouse model

We have determined the presence of impaired behavioral performance in the
hemizygous R1.40 mice manifested by a decline in the long-term memory and the
working memory functions as identified by the retention of the spatial location of the
platform in the Morris water maze and the spontaneous alternations in the Y-maze,
respectively.
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Thus, we examined the ability of a tolfenamic acid treatment of 5 and 50 mg/kg/day to
attenuate such learning and memory deficits in groups of female hemizygous R1.40
transgenic mice aging between 14-21 months. In the Morris water maze task, escape
latency among the treatment and the vehicle groups showed no significant difference
in daily learning acquisition (Fig. 5A). However, ANOVA analysis indicated an
improvement in long-term memory retention in Day 11 probe trial (F(2,15) = 4.145, p
= 0.0369) (Fig. 5B). The Tukey-Kramer HSD post-hoc test showed that mice group
treated with 50 mg/kg/day tolfenamic acid had a significant improvement (HSD =
3.12, p < 0.05) while the treatment with 5 mg/kg/day failed to reach significance
(HSD = 0.71 p ≥ 0.5) (Fig. 5B).
Results from the ANOVA analysis of the spontaneous alternation ratio in the Y-maze
showed a significant improvement in working memory (F(2,15) = 4.479, p = 0.0298)
(Fig. 6). The Tukey-Kramer HSD post-hoc test revealed a significant improvement
with tolfenamic acid treatment of 50 mg/kg/day (HSD = 4.139, p < 0.05), however,
treatment with 5 mg/kg/day did not reach significance (HSD = 1.30, p ≥ 0.05) (Fig. 6)
3.4. Tolfenamic acid treatment lowers SP1 protein without altering Sp1 gene
expression

The protein expressions of cortical SP1 normalized to β-actin was analyzed by
Western blot following treatment with 5 and 50 mg/kg/day for 34 days or with vehicle.
Results analyzed with ANOVA revealed a significant difference in SP1 protein levels
(F(2.11) = 8.747, p = 0.0053) (Fig. 7A). The Tukey-Kramer HSD post-hoc test
indicated a significant decrease of SP1 after treatment with 5 mg/kg/day tolfenamic
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acid (HSD = 4.145, p < 0.05, % change = - 43%) and after treatment with 50
mg/kg/day tolfenamic acid (HSD = 5.712, p < 0.01, % change = - 52%) (Fig. 7A).
Gene expression of Sp1 was evaluated for the different treatment groups as well.
Analysis of Sp1 mRNA levels showed that treatment with tolfenamic acid did not alter
the gene expression of Sp1 (F(2,16) = 0.082, p = 0.922) indicating that the decrease in
SP1 protein levels is not due to a change in its de novo gene expression (Fig. 7B).
3.5. Reduction of APP protein and mRNA following treatment with tolfenamic acid

The protein expressions of cortical APP normalized to β-actin was analyzed by
Western blot following treatment with 5 and 50 mg/kg/day for 34 days or with vehicle.
Results analyzed with ANOVA revealed that APP levels were lowered significantly
(F(2,9) = 8.377, p = 0.009) (Fig. 8A). The Tukey-Kramer HSD post-hoc test indicated
a significant decrease in APP after treatment with 5 mg/kg/day tolfenamic acid (HSD
= 4.877, p < 0.05, % change = - 30.3%) and after treatment with 50 mg/kg/day
tolfenamic acid (HSD = 5.139, p < 0.05, % change = - 32.5%) (Fig. 8A).
In addition to analysis of APP protein levels, APP gene expression was evaluated for
the different treatment groups by Real-Time PCR. ANOVA analysis of APP mRNA
levels revealed a significant decrease in APP gene expression (F(2,15) = 5.238, p =
0.019) (Fig. 8B). The Tukey-Kramer HSD post-hoc test indicated a significant
decrease of APP mRNA after treatment with 5 mg/kg/day tolfenamic acid (HSD =
3.885, p < 0.05, % change = - 50.3%) and after treatment with 50 mg/kg/day
tolfenamic acid (HSD = 4.039, p < 0.05, % change = - 52.3%) (Fig. 8B).
51

3.6. Tolfenamic acid lowers both soluble and insoluble Aβ1–40 and Aβ1–42 levels

We measured the levels of cortical Aβ1–40 and Aβ1–42 levels in the Tris-saline-soluble
and in the insoluble fraction using IBL ELISA kits as described in literature
(Morishima-Kawashima, et al., 2000). ANOVA analysis showed that there was a
significant reduction in soluble Aβ1–40 fraction (F(2,14) = 3.89, p = 0.04) (Fig. 9A) and
the insoluble Aβ1–40 fraction (F(2,14) = 4.95, p = 0.02) (Fig. 9B). The Tukey-Kramer
HSD post-hoc test indicated a significant decrease in soluble Aβ1–40 after treatment
with 50 mg/kg/day (HSD = 3.91, p < 0.05, % change = - 30.1%), however, the
lowering of soluble Aβ1–40 after treatment with 5 mg/kg/day did not reach significance
(HSD = 2.55, p ≥ 0.05, % change = - 21.3%) (Fig. 9A). Multiple group comparison
showed a significant decrease in the insoluble Aβ1–40 fraction after treatment with 5
mg/kg/day (HSD = 3.73, p < 0.05, % change = - 35.2%) and after treatment with 50
mg/kg/day tolfenamic acid (HSD = 3.97, p < 0.05, % change = - 37.4%) (Fig. 9B).
Also, ANOVA analysis showed a significant decrease in soluble Aβ1–42 fraction
(F(2,14) = 6.174, p = 0.012) (Fig. 9C) and the insoluble Aβ1–42 fraction (F(2,14) =
6.343, p = 0.011) (Fig. 9D). The Tukey-Kramer HSD post-hoc test indicated a
significant decrease in soluble Aβ1–42 after tolfenamic acid treatment with 5 mg/kg/day
(HSD = 4.18, p < 0.05, % change = - 22.3%) and after treatment with 50 mg/kg/day
(HSD = 4.518, p < 0.05, % change = - 24.9%) (Fig. 9C). Multiple group comparison
showed a significant decrease in the insoluble Aβ1–42 fraction after treatment with 5
mg/kg/day (HSD = 4.72, p < 0.05, % change = - 31.8%) and after treatment with 50
mg/kg/day (HSD = 4.79, p < 0.05, % change = - 37.7%) (Fig. 9D).
52

We also observed that 5 and 50 mg/kg/day tolfenamic acid treatment reduced total
Aβ1-42/Aβ1-40 ratio -16.3% and -19.9%, respectively. However, this reduction in Aβ1-42
/Aβ1-40 did not reach statistical significance (F(2.14) = 1.788 , p = 0.203).
4. Discussion
Several mechanisms have been proposed to explain how NSAIDs could exert their
effects on AD independent of their COX inhibitory pathways. Certain NSAIDs
including indomethacin, fulfinamic acid, ibuprofen and fenoprofen are agonists for the
nuclear transcriptional regulator peroxisome proliferator-activated receptor-γ (PPARγ)
(Lehmann, et al., 1997; Heneka, et al., 2011) that has been reported to be reduced in
AD brains (Sastre, et al., 2006). PPARγ activation results in a reduction in the levels
of Aβ-induced proinflammatory response of microglia and monocytes, and promotes
Aβ clearance by astrocytes and microglia (Matsuo, et al., 1996; Combs, et al., 2000;
Daynes and Jones, 2002; Yue and Mazzone, 2009; Mandrekar-Colucci, et al., 2012).
In addition, a PPARγ responsive element (PPRE) has been identified in the BACE1
gene promoter that is repressed by PPARγ binding resulting in a decrease in BACE1
expression (Sastre, et al., 2003; Sastre, et al., 2006). Weggen et al., reported that a
subset of NSAIDs specifically lowers Aβ1-42 that was accompanied by a parallel
increase in Aβ1-38 suggesting a minor γ-secretase modulatory effect without alteration
of the Notch pathway (Weggen, et al., 2001). The specific Aβ1-42 inhibition by that
subset of NSAIDs was further studied by Zhou et al., and concluded that the
involvement of Rho-Rock pathway in regulating APP processing, and inhibition of
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Rho activity by specific NSAIDs could preferentially reduce Aβ1-42 (Zhou, et al.,
2003).
Tolfenamic acid, of all other NSAIDs, has the unique mechanism of inducing the
proteasome dependent degradation of SP transcription factors including SP1, SP3 and
SP4 and thereby, decreasing the expression of vascular endothelial growth factors
(VEGF) (Abdelrahim, et al., 2006), which is involved in tumor progression and
metastases. Because of its SP degradation effects, tolfenamic acid has been studied
and research has confirmed its antitumor effects (Abdelrahim, et al., 2006; Konduri, et
al., 2009; Basha, et al., 2011; Colon, et al., 2011).
Sp1 involvement in AD has been researched and it was found that its expression was
elevated in the frontal cortex of human AD brains as well as in the brains of transgenic
mouse models of AD (Santpere, et al., 2006; Citron, et al., 2008). The elevation of Sp1
was accompanied by an increase in COX-2, another Sp1 target gene, suggesting
interplay between inflammatory processes and Sp1 driven gene expression (Citron, et
al., 2008). Sp1 binds to 5’-GGGGCGGGGC-rich promoter genes such as APP and
BACE1 genes, which are involved in AD pathology, and Sp1 overexpression leads to
induction of their protein expression (Cai, et al., 2001; Christensen, et al., 2004;
Citron, et al., 2008). We have reported that silencing of Sp1 gene by siRNA resulted in
70% decrease in the responsiveness of the human APP promoter (Basha, et al., 2005).
Also, we have shown the co-localization of APP, Sp1 and Aβ in various regions of the
brain (Brock, et al., 2008). Thus, we had proposed the hypothesis that tolfenamic acid
could interrupt the de novo synthesis of APP and consequently, alter the downstream
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levels of Aβ. This hypothesis was confirmed when oral treatment with tolfenamic acid
resulted in degradation of SP1 that was accompanied by a reduction in cortical and
hippocampal APP gene expression and protein and Aβ peptide levels (Adwan, et al.,
2011). This was further supported by measurements which demonstrated the presence
of tolfenamic acid in the brain following IV administration (Subaiea, et al., 2011).
In the present study, we demonstrate that hemizygous R1.40 transgenic mice exhibit
cognitive deficits upon assessment of their working memory and long-term memory
retention even before the reported age at which hemizygous R1.40 start to show
extensive β-amyloid deposition (Lamb et al., 1999). Spatial learning was assessed in
the hidden version of the Morris water maze and we found that the transgenic mice
were able to learn escaping to the hidden platform in the daily training sessions (Fig.
3A). However, they exhibited memory retention impairments in the probe trials as
they failed to memorize the spatial location of the hidden platform with increased
delay (Fig. 3B, Day 11). In addition, working memory assessed in the Y-maze was
impaired in these mice with numerous alternation errors and a lowered alternation
ratio compared to the WT control group (Fig. 4). It has been proposed that recent
spatial memory is hippocampal-dependent, while remote spatial memory is dependent
on the integrity of the medial prefrontal cortex (King, et al., 1999; Frankland and
Bontempi, 2005; Teixeira, et al., 2006). In turn, working memory assessed in the Ymaze is hippocampal and cortical-dependent (Lalonde, 2002). That, together with the
findings that the R1.40 mouse model exhibits extensive amyloid deposition in the
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cortical region compared to that observed in the hippocampal formation (Hock, et al.,
2009), may explain the observed results.
We report here that short-term tolfenamic acid administration was able to improve the
mnemonic deficits observed in hemizygous R1.40. We found that 50 mg/kg/day
tolfenamic acid was able to reverse the long-term memory retention deficits seen in
delayed probe trial of the Morris water maze experiment (Fig. 5B). In addition, the 50
mg/kg/day treatment group showed significant improvement in the Y-maze with less
error in spontaneous alternations (Fig. 6). However, the short-term treatment with 5
mg/kg/day showed only modest effects in reversing the memory deficits in the mice.
Analysis of amyloid pathology markers indicated that both treatment regimens, 5 and
50 mg/kg/day, were able to significantly lower the protein level of SP1 without
altering it gene expression (Fig. 7A and 7B), similar to our previous findings in the
C57BL/6 treated with tolfenamic acid (Adwan, et al., 2011). In addition, both
tolfenamic acid doses significantly reduced the protein levels of APP and its gene
expression (Fig. 8A and 8B). Furthermore, levels of the soluble and insoluble Aβ1–40
and Aβ1–42 were reduced by tolfenamic acid with a trend toward lowering the insoluble
fractions of Aβ more than that of the soluble fraction. It is possible that tolfenamic
acid may aid in clearance of insoluble Aβ by a PPARγ activation, however, it is not
clear yet if tolfenamic acid activates PPARγ as certain other NSAIDs do.
While tolfenamic acid was effective in lowering the amyloidogenic proteins with both
doses, we observed dose-dependent improvement in the cognitive deficits. Whether
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longer period of treatment with low dose tolfenamic acid could result in significant
improvements in cognitive function is yet to be studied.
In conclusion, tolfenamic acid is unique among NSAIDs in its ability to inhibit Sp1
and thus interrupt APP de novo synthesis and its Aβ products. In this study, we
demonstrated that short-term administration of tolfenamic acid for 34 days reversed
the cognitive deficits in hemizygous R1.40 transgenic mice. Consistent with our
previous published findings in C57BL/6 mice, SP1, the amyloidogenic levels of APP
and soluble and insoluble Aβ1–40 and Aβ1–42 were markedly lowered by tolfenamic
acid in AD transgenic mice. These data provide further evidence that tolfenamic acid
could be a promising therapeutic approach as a repurposed AD drug acting through an
alternative mechanism.
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Figure II-1. A timeline of tolfenamic acid administration and behavioral
assessment. Mice were administered tolfenamic acid daily for 34 days. Behavioral
testing in the Morris water maze began on the 15th day of dosing with daily training
sessions that lasted until the 23rd day of the study. On the 24th day of dosing, we
conducted the first session of probe trials (Day 1) and then we performed a second
session of probe trials on the 34th of dosing (Day 11), to assess for long-term memory
retention. Trials for the spontaneous alternations in the Y-maze were conducted on the
33rd day of dosing as well. Animals were euthanized on the 35th day of the study and
brain tissue was dissected, collected and stored in the -80°C freezer.
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Figure II-2. Genotyping of in-house bred APP YAC transgenic mice, line R1.40.
Genetic identification and allelic discrimination was performed using standard
protocols (see methods section). A) Genetic identification of YAC APP transgenic
(Tg) and non-transgenic (non-Tg) mice using standard PCR protocol; B) A scatter plot
of allelic discrimination analysis.
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Figure II-3. Memory impairments in hemizygous APP YAC transgenic mice, line
R1.40, assessed by the swimming task in the Morris water maze. A) Acquisition
patterns during daily training. B) Probe trials for long-term memory retention on Days
1 and 11 following acquisition-training trials. “*” indicates that the values are
significantly different from control, as determined by a Student’s t-test (p<0.05).
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Figure II-4. Working memory impairments in hemizygous APP YAC transgenic
mice, line R1.40. Mice were examined for working memory function assessed by
measuring the spontaneous alternation ratio in the Y-maze. “**” indicates that the
values are significantly different from control, as determined by a Student’s t-test
(p<0.01)
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Figure II-5. Effects of the administration of tolfenamic acid to hemizygous APP
YAC transgenic mice, line R1.40. Tolfenamic acid was administered daily by oral
gavage for 34 days. See the methods section for details. A) Acquisition patterns during
daily training trials of 5 mg/kg/day, 50 mg/kg/day and vehicle groups B) Probe trials
assessing the long-term memory retention on Days 1 and 11 following acquisitiontraining trials. “*” indicates that values are significantly different from control, as
determined by ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs
of columns (p<0.05), obtained using GraphPad InStat 3 software. Vehicle n=6; 5
mg/kg/day n=6; 50 mg/kg/day n=7.
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Figure II-6. Working memory improvement in hemizygous APP YAC transgenic
mice, line R1.40, after administration of tolfenamic acid assessed by the
spontaneous alternations in Y-maze. Tolfenamic acid was administered daily by oral
gavage for 34 days. See the methods section for details. “*” indicates that values are
significantly different from control vehicle, as determined by ANOVA analysis with
Tukey-Kramer post-hoc test to compare all pairs of columns (p<0.05), obtained using
GraphPad InStat 3 software. Vehicle n=6; 5 mg/kg/day n=6; 50 mg/kg/day n=7.
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Figure II-7. Reduction of SP1 protein levels in the brain after treatment with
tolfenamic acid. Tolfenamic acid was administered daily by oral gavage for 34 days.
See the methods section for details. A) Western blot analysis of cortical SP1 levels as
a ratio to the house keeping protein β-actin after treatment with 5 and 50 mg/kg/day of
tolfenamic acid for 34 days. B) Cortical Sp1 mRNA levels determined by Real-Time
PCR. “*” indicates that values are significantly different from control, as determined
by ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs of columns
(∗p<0.05, ∗∗p<0.01), obtained using GraphPad InStat 3 software.
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Figure II-8. Reduction of amyloid precursor protein (APP) levels in the brain
after treatment with tolfenamic acid. Tolfenamic acid was administered daily by
oral gavage for 34 days. See the methods section for details. A) Western blot analysis
of cortical APP levels as a ratio to the house keeping protein β-actin after treatment
with 5 and 50 mg/kg/day of tolfenamic acid for 34 days. B) Cortical APP mRNA
determined by Real-Time PCR. “*” indicates that values are significantly different
from control, as determined by ANOVA analysis with Tukey-Kramer post-hoc test to
compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.
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Figure II-9. Reduction of soluble and insoluble Aβ1-40 and Aβ1-42 levels in the
brain after treatment with tolfenamic acid. Tolfenamic acid was administered daily
by oral gavage for 34 days. See the methods section for details. Aβ levels were
quantified by ELISA in the cortices of mice treated with 5 and 50 mg/kg/day of
tolfenamic acid for 34 days. (A) Soluble Aβ1-40, (B) Insoluble Aβ1-40, (C) Soluble Aβ142

and (D) Insoluble Aβ1-42 levels. “*” indicates that values are significantly different

from control, as determined ANOVA analysis with Tukey-Kramer post-hoc test to
compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.
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ABSTRACT
BACKGROUND: We have reported that tolfenamic acid treatment decreases
amyloidogenic proteins in wild type and transgenic mice via lowering of the
transcription factor specificity 1 protein (Sp1).
OBJECTIVES: In this study, we examine the ability of tolfenamic acid to reduce the
amyloid plaque burden in R1.40 mouse model, as well as to ameliorate spatial learning
and memory deficits in R1.40 and senescent wild type mice.
METHODS: Behavioral and immunohistochemical analyses were performed
following the oral administration of multiple doses of tolfenamic acid to homozygous
R1.40 and senescent wild type mice for 34 days.
RESULTS: Quantitative immunohistochemical analysis indicated that tolfenamic acid
treatment resulted in a profound decrease in cerebral amyloid beta (Aβ) plaque burden.
The reduction in the amyloid pathology was accompanied by improvements in spatial
working memory assessed by spontaneous alternation ratio in the Y-maze. In addition,
senescent wild type mice treated with tolfenamic acid exhibited improved spatial
reference memory performance in the delayed probe trials of the Morris water maze
compared to the non-treated group.
CONCLUSION: These results provide further evidence that tolfenamic acid could be
utilized as a repurposed drug to modify Alzheimer’s disease (AD) pathogenesis.
Keywords: Alzheimer’s disease; tolfenamic acid; AD transgenic mouse model;
learning and memory; Morris water maze; Y-maze; immunohistochemistry; amyloid
plaque burden.
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1. Introduction
Alzheimer’s disease (AD) patients suffer from profound general memory loss and
dementia until death and the disease is known as the most prevalent neurodegenerative
disorder [1]. Even though Alois Alzheimer has described the disease for more than a
century, no cure has been discovered yet [2, 3]. Different brain regions especially in
the cerebral cortex, hippocampus, subcortical nuclei and amygdala suffer extracellular
senile plaques and intraneuronal neurofibrillary tangles (NFTs) formation that
characterize the neuropathological deposits identified in AD [2, 4]. Neuritic plaques
induce the proliferation of astrocytes and microglia with altered morphology leading
to inflammatory responses that contribute to the brain degeneration observed in the
disease [5, 6].
Senile plaques are mainly composed of aggregated amyloid beta (Aβ) peptides, which
are 38-43 amino acids long, that are generated by the cleavage of the amyloid
precursor protein (APP) by the beta-site APP-cleaving enzyme 1 (BACE1) and γsecretase [7, 8]. The formation of the insoluble Aβ depositions depends on the rate of
Aβ production and the rate of its elimination. Thus, the amyloid hypothesis of AD was
developed, suggesting that amyloid plaque aggregates formed by the amyloidogenic
breakdown of APP cause the neurodegeneration and dementia seen in AD [9].
Current FDA approved medications for AD are not disease-modifying therapies and
do not stop the progression of AD [10]. Tolfenamic acid, a non-steroidal antiinflammatory drug (NSAID), induces the degradation of the transcription factor
specificity protein 1 (Sp1) [11]. Sp1 regulates the expression of several AD-related
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genes, and its expression is elevated in the frontal cortex of human AD brains as well
as in the brains of transgenic mouse models of AD [12, 13]. We have previously
provided proof-of-concept that tolfenamic acid interrupts the de novo synthesis of APP
and consequently, alters the downstream levels of Aβ [14]. Treatment of wild type
C57BL/6 mice with tolfenamic acid lowered the levels of Sp1 protein (SP1) and the
expression of AD-related Sp1 target genes including APP [14], tau and BACE1
(unpublished observations), and was supported by measurements which demonstrated
the presence of tolfenamic acid in the brain following IV administration [15]. In
addition, data from our lab showed that tolfenamic acid reversed the cognitive deficits
in the hemizygous R1.40 transgenic mouse model of AD and lowered the levels of
SP1, APP and soluble and insoluble Aβ1–40 and Aβ1–42.
The purpose of the current study was to investigate the ability of tolfenamic acid to
lower Aβ plaque load in old homozygous R1.40 mice that exhibit fibrillar plaque
depositions between the ages of 14 and 15 months [16, 17]. Furthermore, we
investigated if tolfenamic acid would ameliorate the cognitive impairments even long
after plaque deposition has begun in homozygous R1.40 mice. In addition, we also
administered tolfenamic acid to senescent wild type mice to determine whether the
treatment could enhance their mnemonic functions as they express age-related spatial
working and reference memory decline in the absence of plaque deposition.
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2. Methods
2.1. Animal model

Wild type mice and a genomic-based transgenic mouse model, R1.40, were utilized
for this study. The transgenic mice, developed by Bruce T. Lamb, were obtained from
the Jackson laboratory (Bar Harbor, ME, USA) and colonies of homozygous strains
were established in-house. The R1.40 mouse model utilizes a yeast artificial
chromosome (YAC) that includes the full 400 kb human APP gene and the flanking
sequence

of

approximately

250

kb

to

harbor

the

Swedish

mutation

APPK670N/M671L and human transcriptional regulatory elements, allowing for
proper spatial and temporal expression [18-20]. The mnemonic deficits in
homozygous R1.40 are similar to those observed in AD and the model shows a great
increase in APP and Aβ production with Aβ deposition occurring at 14-15 months of
age compared to the wild type [21, 22].
Mice colonies were established in-house at the University of Rhode Island (URI)
animal quarter facility. Mice were bred and genotyped using two genotyping
techniques including standard PCR followed by gel electrophoresis, and was
confirmed using the TaqMan® allelic discrimination assay (Applied Biosystems,
Foster City, CA, USA). Mice of different genotypes were housed in standard mouse
cages in rooms with temperature maintained at 22±2°C with humidity levels of
55±5%. The rooms were set for 12:12 hr light-dark cycle (light on 6:00 AM, light off
at 6:00 PM) and the animals were provided with food and water ad libitum. A URI
veterinarian continuously supervised the animals during the entire period of the study
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and assisted in drug administration. All the protocols including breeding and
genotyping techniques were approved by the URI Institutional Animal Care and Use
Committee (IACUC).
2.2. Animal exposure to tolfenamic acid and behavioral testing

Tolfenamic acid was obtained from Sigma Aldrich (St. Louis, MO, USA) and
homozygous APP YAC transgenic mice of mixed gender aging between 19-24 months
were used to examine the ability of the drug to reduce the amyloidogenic plaque load
and to improve the learning and memory deficits observed in these mice. The animals
were divided into three groups of similar age and gender variation and were
administered tolfenamic acid daily via oral gavage for 34 days; one group was
administered 5 mg/kg/day tolfenamic acid in corn oil (n=7); the second group was
administered 50 mg/kg/day tolfenamic acid in corn oil (n=6) and the third group was
administered corn oil, the vehicle, (n=7). In addition, tolfenamic acid was
administered to old wild type mice of mixed gender aging between 18-24 months in
order to study its effects on learning and memory. The animals were divided into three
groups of similar age and gender variation and were administered tolfenamic acid
daily via oral gavage for 34 days; one group was administered 5 mg/kg/day tolfenamic
acid in corn oil (n=11); the second group was administered 50 mg/kg/day tolfenamic
acid in corn oil (n=10) and the third group was administered corn oil, the vehicle,
(n=13).
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2.3. Assessment of cognitive functions following tolfenamic acid treatment in
homozygous R1.40 transgenic mice and wild type mice

Memory and cognitive functions in homozygous R1.40 transgenic and wild type mice
were characterized through behavioral testing in mazes that examine the integrity of
the hippocampus and the brain cortex including the Morris water maze and
spontaneous alternations in the Y-maze. After 14 days of daily dosing, testing began in
the Morris water maze and on Day 33 mice were tested for spontaneous alternations in
Y-maze. Finally, on Day 35, mice were euthanized and brains were extracted.
2.3.1. Morris water maze

Mice were tested in the hidden version of the Morris water maze where they had to
locate a hidden platform by learning multiple spatial relationships between the
platform and the distal extra-maze cues [23-25]. The apparatus consisted of a white
48” diameter pool that is 30” in height and was filled with water to a depth of 14”.
Non-toxic washable liquid paint was added to the water to keep it opaque. Distinct
fixed visual cues surrounded the pool that the animals used for navigation while
trying to reach the escape platform. A clear Plexiglas platform square of 10 cm was
kept submerged 0.5 cm below the surface of the water. The temperature of the water
was always kept around 25 ±2°C during all procedures in the water maze.
Habituation trial in which mice were allowed to swim freely for 60 sec to acclimate
to the procedure was conducted on Day 15 of drug administration. On the following
day and for a total of 8 days, mice received training sessions of three trials daily. For
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each trial, the starting position was randomly assigned between the four possible
positions while the platform position was kept the same for the entire training
sessions.
Each animal was allowed to swim until it found the immersed hidden platform or for
a maximum duration of 60 sec. A mouse that failed to locate the platform in the first
60 sec would be gently guided to sit on the platform for a maximum duration of 30
sec. Upon a successful trial, the mouse would be left to sit on the platform for a
maximum of 10 sec. Following conducting the eight acquisition sessions, probe
trials for up to 60 sec on Day 1 and Day 11 following the last day of training were
performed to assess the long-term memory retention. This was achieved by studying
the preference of the mice to swim in the correct quadrant that previously contained
the hidden platform. All trials including the swim paths and latencies to locate the
platform were videotaped and tracked with a computerized video tracking system
(ObjectScan, Clever Sys. Inc., Reston, VA, USA) and the resultant data were
analyzed.
2.3.2. Spontaneous alternations in the Y-maze

The spontaneous alternation ratio, defined as the percentage of the number of arm
entries, different from the previous two entries, divided by the total arm entries
minus two was measured [22, 26]. Testing trials were conducted in a white Y-maze
with arms that were 12” (long) by 3” (wide) with 8” height walls. Mice were placed
into one of the Y-maze arms and were left to explore the maze freely for 5 minutes.
After each trial, the maze was cleaned with 70% ethanol. Y-maze trials were
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videotaped and tracked with a computerized video tracking system (ObjectScan,
Clever Sys. Inc., Reston, VA, USA) and the data were analyzed.
2.4. Tissue preparation

Following 34 days of daily administration of tolfenamic acid and on Day 35,
homozygous R1.40 mice were deeply anesthetized with an intraperitoneal injection of
0.1 ml/10g of xylazine-ketamine mixture (100 mg/ml-10 mg/ml) and were perfused
transcardially with 100 ml of perfusion wash that consisted of 0.8% sodium chloride,
0.8% sucrose, 0.4% dextrose, 0.034% anhydrous sodium cacodylate and 0.023%
calcium chloride. After that, mice were perfused with 100 ml of perfusion fix that
consisted of 4% paraformaldehyde, 4% sucrose and 1.07% anhydrous sodium
cacodylate and the brains were removed. The extracted brains were post-fixed in the
perfusion fix solution overnight and then they were cryopreserved in 30% sucrose
solution. Fixed brains were subject to coronal sectioning (40 µm) and collection using
MultiBrain® Technology (NeuroScience Associates, Knoxville, TN, USA) and
sections were stored in preservative fix at -20°C. MultiBrain® Technology allows
brains from different groups to be embedded together in the solid matrix and to be
processed as a single unit. That enabled treatment of different brain sections under the
same conditions providing more built-in quality control leading to obtaining uniform
staining. For the wild type group, on Day 35, the mice were anesthetized with carbon
dioxide, euthanized and their brains were extracted and stored at -80°C.
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2.5. Immunohistochemistry

To identify and quantify amyloid plaques in brain sections from different groups, freefloating sections were taken from the preservative solution and were washed with
distilled water. That was followed by washing with 1X phosphate buffer saline (PBS)
three times, three min each. After that, sections were immersed in a solution of 3%
hydrogen peroxide (H2O2) for 30 min to quench the endogenous peroxidase activity.
Sections were rinsed three times with PBS for three min each and then incubated in
70% formic acid solution for 30 min at room temperature. The sections were washed
with PBS three times, three min each and were incubated in 3% bovine serum albumin
(BSA) and 0.1% Triton X-100 for 30 min. After rinsing with PBS, sections were
Incubated with 1

antibody against Aβ (6E10, Sig-39320, Covance, Dedham, MA,

USA) of 1:200 dilution overnight at 4°C. That was followed by incubation with the
appropriate

species-specific

biotinylated

secondary

antibody

(Vector

Labs,

Burlingame, CA, USA) of 1:500 dilution for 30 min and then the sections were
incubated with horseradish peroxidase HRP-conjugated streptavidin (Vector Labs,
Burlingame, CA, USA) for 30 min. After that, sections were washed with PBS and the
immunoreactivity

was

detected

and

visualized

with

the

substrate

3-3,

diaminobenzidine (DAB) (Vector Labs, Burlingame, CA, USA). Brain sections were
counterstained with hematoxylin. The sections were mounted on microscope slides
according to procedure provided by NeuroScience Associates and coverslips were
mounted with permanent mounting medium (Vector Labs, Burlingame, CA, USA).
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2.6. Quantification of Aβ plaques

Evaluation of the extracellular Aβ plaque load in the cerebral cortex was performed
using a Nikon Eclipse E600 microscope (Nikon, Melville, NY, USA) attached with a
Diagnostic Instruments digital camera and using SPOT Diagnostic Instruments
software (Diagnostic Instruments, Sterling Heights, MI, USA). Serial images of 10X
magnification were captured on four sections per animal that were 80 µm apart from
each other. Using ImageJ software from NIH (Bethesda, MD, USA), the images were
binarized to 16-bit grey scale and were segmented to distinguish the aggregates from
background. The minimum and maximum size was set to exclude objects in the image
that were clearly not of interest and data were collected including size, number and
area of the plaques. Amyloid burden was expressed as the percent area stained positive
for Aβ to the total area analyzed.
2.7. Statistical analysis
The significance of difference between different treatment groups was determined
by repeated measure analysis of variance (ANOVA) and Tukey-Kramer multiple
comparison post-hoc test. Data are expressed as the mean ± the standard error of the
mean (SEM). All statistical analyses were conducted using GraphPad InStat 3
software (GraphPad Software, La Jolla, CA, USA)and probability (p) value of <0.05
was considered acceptable for statistical significance.
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Results
3.1. Treatment with tolfenamic acid attenuates the cognitive deficits in homozygous
R1.40 mouse model

We examined the effects of tolfenamic acid treatment of 5 and 50 mg/kg/day on
learning and memory in groups of old homozygous R1.40 transgenic mice aging
between 19-24 months. There was a significant effect of training as ANOVA analysis
showed that the difference in escape latency between the first and the last day of
training sessions was statistically significant (F(7,152) = 7.293, p < 0.0001). The
results showed that in the Morris water maze, the difference in the escape latency
during the training phase between different experimental groups was not statistically
significant. However, the tolfenamic acid treated groups showed a trend of better
performance than the control vehicle group through days 4-8 of the training sessions
(Fig. 1A). Analysis of probe trials Day 1 and Day 11 indicated that while both
tolfenamic acid treatment groups scored higher percentages in the correct quadrant
than the control group in both probe trials, the difference was not statistically
significant (p ≥ 0.05) (Fig. 1B).
Nevertheless, results from repeated measures ANOVA analysis of the spontaneous
alternation ratio in the Y-maze showed a significantly improved working memory
function (F(2,14) = 4.495, p = 0.0311) (Fig. 2). The Tukey-Kramer HSD post-hoc test
indicated a significant effect of 50 mg/kg/day tolfenamic acid treatment in improving
spatial working memory (HSD = 3.702, p < 0.05), while the treatment with 5
mg/kg/day did not reach significance (HSD = 0.91, p ≥ 0.05) (Fig. 2).
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3.2. Effects of tolfenamic acid treatment on spatial learning and memory in old wild
type mice

Several studies have reported age-related spatial memory impairments and thus we
wanted to examine whether tolfenamic acid treatment could alter learning and memory
in old C57BL/6 mice. Again, there was a significant effect of training as ANOVA
analysis showed that the difference in escape latency between the first to the last daily
training sessions was statistically significant (F(7,264) = 8.858, p < 0.0001) (Fig. 3A).
Our results showed that in the Morris water maze task, the escape latency during the
training phase of the different experimental groups was not statistically significant.
However, repeated measures ANOVA analysis of probe trial Day 11 revealed a
significant improvement in the spatial reference memory function (F(2,29) = 4.811, p
= 0.0291) (Fig. 3B). The Tukey-Kramer HSD post-hoc test showed that mice group
treated with 5 mg/kg/day tolfenamic acid dose had a significant improvement (HSD =
3.828, p < 0.05) while difference in percent time mice spent in the correct quadrant
after treatment with 50 mg/kg/day versus the control group did not reach statistical
significance (HSD = 2.632, p ≥ 0.5) (Fig. 3B).
In the Y-maze, ANOVA analysis of spontaneous alternation ratio did not indicate a
significant difference between different treatment groups (F(2,30) = 0.451, p = 0.641)
(Fig. 4).
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3.3. Tolfenamic acid treatment significantly reduces Aβ amyloid deposition in aged
homozygous R1.40 mice

As described in the literature, the homozygous R1.40 mouse model develops
extracellular Aβ plaques that start to be evident between the ages of 14 and 15 months
[16, 17]. Tolfenamic acid treatment with both doses greatly reduced amyloid plaque
pathology in multiple cerebral cortical regions such as the primary somatosensory
cortex, parietal association cortex, auditory cortex and insular cortex, compared to
non-treated mice (Fig. 5A). Quantitative immunohistochemistry analysis revealed that
tolfenamic acid treatment for 34 days significantly lowered Aβ plaque deposition
F(2,14) = 6.685, p = 0.009) (Fig. 5B). The Tukey-Kramer HSD post-hoc test indicated
that 5 and 50 mg/kg/day tolfenamic acid doses lowered amyloid deposition
significantly (HSD = 3.779, p < 0.05 and HSD = 5.012 p < 0.01, respectively) (Fig.
5B). Consistent with previously reported data describing the pathology and the
behavioral deficits in homozygous R1.40 [22], there was no correlation between the
extent of Aβ deposition and the time spent in the correct quadrant during the probe
trials conducted in Day 1 and Day 11 following the training sessions (Day 1 retention,
r(17) = 0.049, p > 0.1; Day 11 retention, r(17) = -0.113, p > 0.1). However, there was
a significant correlation between the plaque burden and the spontaneous alternation
ratio (r(17) = -0.482, p = 0.042).
3. Discussion
Certain NSAIDs have been shown to alter AD pathology and attenuate learning and
memory deficits in murine mouse models of AD by mechanisms other than their
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classic cyclooxygenase (COX) inhibition pathway and have led researchers to
consider such NSAIDs as potential disease-modifying agents for AD [27-29].
Tolfenamic acid, of all other NSAIDs, has the unique mechanism of inducing the
proteasome-dependent degradation of SP transcription factors including SP1, SP3 and
SP4 and thereby, decreasing the expression of the vascular endothelial growth factors
(VEGF), which is involved in tumor progression and metastases [11]. Elevated levels
of Sp1 have been found in the frontal cortex of the brains of AD patients as well as in
the brains of transgenic mouse models of AD [12, 13]. Interplay between
inflammatory processes and Sp1-driven gene expression has been suggested, as the
elevation of Sp1 was accompanied by an increase in COX-2 expression, an Sp1 target
gene [12].
Sp1 induces the expression of genes involved in AD pathology which include APP,
BACE1 and tau as their promoter regions are rich with 5’-GGGGCGGGGC- sequence
that Sp1 binds to [12, 30, 31]. Thus, we hypothesized and we showed that tolfenamic
acid could interrupt the de novo synthesis of APP and alter the downstream levels of
Aβ in C57BL/6 mice [14] and hemizygous R1.40 transgenics leading to improvements
in learning and memory profiles.
As a genomic-based transgenic mouse model of AD, R1.40 line represents a valuable
tool for assessing the effects of potential AD therapeutics in reducing amyloidogenic
pathology and in improving learning and memory profiles. At 14-15 months of age,
homozygous R1.40 mice exhibit depositions of extracellular Aβ plaques accompanied
by cognitive deficits [16, 17, 22]. The mice demonstrate the ability to learn the
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location of the hidden platform during daily training session trials in the Morris water
maze; however, they exhibit a decline in long-term memory retention compared to
non-transgenic mice as assessed by probe trials. In addition, when these mice were
assessed for the spontaneous alternation ratio in the Y-maze, impairments in the
working memory functions were observed [22].
The present study provides the first evidence of the ability of a relatively short-term
tolfenamic acid treatment to reduce Aβ plaque burden drastically in homozygous
R1.40 compared to longer treatments for 6-9 months in other transgenic models with
another NSAID, namely ibuprofen [32, 33]. It was also observed that tolfenamic acid
treatment results in a greater lowering of Aβ peptide levels in wild type C57BL/6 and
hemizygous R1.40 mice compared to the reduction of APP ([14]; unpublished data),
indicating that additional mechanisms responsible for plaque degradation and
clearance of Aβ are involved.
We also examined the ability of tolfenamic acid treatment to attenuate the spatial
memory deficits observed in old homozygous R1.40 mice aging between 19-24
months, which have been suffering from Aβ plaque deposition reported to start as
early as 14 months of age [21]. We found that both doses of 5 and 50 mg/kg/day
resulted in a trend of shorter latency during daily Morris water maze training trials and
higher percentage in the correct quadrant during both probe trials compared to the
vehicle treated group. However, those differences from the vehicle treated group did
not reach statistical significance.
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We exposed animals to tolfenamic acid at senescence whilst the combined effect of
age and the mutant transgene persisted. Thus, lowering the amyloidogenic pathology
may not have been sufficient enough to retrieve enough spatial reference memory
capabilities to perform significantly well in the Morris water maze compared to the
non-treated group. At the onset of tolfenamic acid exposure, the extensive plaque
pathology in different cortical regions has been in effect for a long period of time. It is
well known that Aβ plaques are toxic, affect synaptic plasticity, and stimulate the
production of reactive oxygen species (ROS) leading to elevations in the oxidative
stress and neuronal cell death. It is possible that the damage by Aβ deposition on
memory networks was extensive and irreversible by the time treatment started, even
though tolfenamic acid treatment reduced the plaque burden significantly.
Alternatively, there may be a lesser connection between spatial memory functions and
the plaque burden. The previous explanation is supported by the fact that tolfenamic
acid significantly improved mice performance in the spontaneous alternations in the
Y-maze. The spontaneous alternations task is mainly dependent on the hippocampus
and the prefrontal cortex [34], and as described in the literature, R1.40 mice only show
scattered Aβ plaque deposition in hippocampal formation [16, 22] which is in
consistency with our observations (data not shown).
In aged wild type C57BL/6 mice, short-term tolfenamic acid administration was able
to improve certain spatial mnemonic deficits. Data analysis of Morris water maze
probe trial in Day 11 shows that tolfenamic acid significantly improved spatial
reference memory while there was no effect in improving the spatial working memory
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assessed by spontaneous alternations in the Y-maze. Wild type mice do not develop
amyloid plaque pathology, however, tolfenamic acid reduces APP and Aβ levels in
C57BL/6 mice [14]. It is not clear if the improved spatial reference memory was due
to the reduction of Aβ levels or due to tolfenamic acid’s effects on other pathways
mediated by COX inhibition or by non-COX effects.
We have found that Aβ levels in hippocampus were lowered by tolfenamic acid [14],
however, spontaneous alternation ratio was not altered by tolfenamic acid treatment. It
is possible that non-amyloidogenic processes that are not altered by tolfenamic acid
treatment are contributing strongly to the age-related spatial working memory
impairments in C57BL/6 mice. For example, those deficits were explained as due to
alterations in the synaptic plasticity within the hippocampal formation [35] that were
attributed to changes in the functional properties of NMDA receptors and changes in
calcium homeostasis [36-38]. Fordyce and Wehner suggested that reduction in the
activity membrane-bound protein kinase C (PKC) in the hippocampus was associated
with the age-related decline in spatial learning and memory [39]. In addition, the
increase in reactive oxygen species (ROS) and brain oxidative stress is another
mechanism involved in age-related behavioral deficits [40, 41]. Furthermore, it has
been reported that hippocampal glucose levels depletion contributes to memory
dysfunction, and that systemic glucose administration reverses the age-dependent
decrease in the spontaneous alternation ratio [42, 43].
Consistent with our prior findings in hemizygous R1.40 mice, the present study
indicates that tolfenamic acid is effective in lowering the amyloidogenic proteins and
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Aβ plaques with both doses, with dose-dependent improvements in cognitive deficits.
We still have to study the effects of extended period of tolfenamic acid exposure with
low doses as it may result in significant improvements in cognitive functions. It is
essential to mention that compared to other FDA approved AD drugs and NSAIDs,
tolfenamic acid significantly decreased plaque pathology and produced significant
behavioral improvements in a relatively short duration of treatment. For example, 0.58
mg/kg/day donepezil, an FDA-approved anticholinesterase drug for AD, improved
performance in the Morris water maze after two months of treatment in APP23
transgenic mice [44]. Another FDA-approved drug for use in moderate to severe AD,
memantine, improved cognition in 3x TG-AD mice after three months of treatment
[45]. In addition, ibuprofen was able to produce improvement in cognitive functions in
triple transgenic mice (APPswe, PS1M146V and tauP301L) following its
administration for six months [46].
In conclusion, we report that tolfenamic acid treatment drastically reduces Aβ plaque
pathology that is accompanied by improvement in spatial learning and memory in a
murine mouse model of AD. This occurs within a period that is much shorter than that
observed with other NSAIDs. Our data suggest that tolfenamic acid treatment can also
combat certain age-related mnemonic deficits in wild type mice. The data provide
further evidence of the ability of tolfenamic acid, through Sp1 reduction, to disrupt the
development and the progression of the pathological processes of AD. Thus,
tolfenamic acid, as a repurposed AD drug, could be a promising disease-modifying
therapeutic agent acting through an alternative mechanism.
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Figure III-1. Effects of tolfenamic acid on spatial reference memory in
homozygous R1.40 mice. Tolfenamic acid was administered by oral gavage daily for
34 days and behavioral testing was conducted in the Morris water maze. See the
methods section for details. A) Acquisition patterns during daily training trials for the
5 mg/kg/day, 50 mg/kg/day and vehicle groups; B) Probe trials assessing the longterm memory retention on Days 1 and 11 following acquisition training trials. Data
were analyzed by ANOVA with Tukey-Kramer post-hoc test to compare all pairs of
columns, obtained using GraphPad InStat 3 software. Vehicle n=7; 5 mg/kg/day n=7;
50 mg/kg/day n=6.
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Figure III-2. Working memory improvement in homozygous R1.40 transgenic
mice after administration of tolfenamic acid. Tolfenamic acid was administered by
oral gavage daily for 34 days. Working memory was assessed by spontaneous
alternations in the Y-maze. See the methods section for details. “*” indicates that
values are significantly different from control vehicle, as determined by ANOVA
analysis with Tukey-Kramer post-hoc test to compare all pairs of columns (p<0.05),
obtained using GraphPad InStat 3 software. Vehicle n=7; 5 mg/kg/day n=7; 50
mg/kg/day n=6.
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Figure III-3. Administration of tolfenamic acid to old wild type mice alters
spatial reference memory. Tolfenamic acid was administered by oral gavage daily
for 34 days. Spatial reference memory was tested in the Morris water maze. See the
methods section for details. A) Acquisition patterns during daily training trials for the
5 mg/kg/day, 50 mg/kg/day and vehicle groups. B) Probe trials assessing the longterm memory retention on Days 1 and 11 following acquisition training trials. “*”
indicates that values are significantly different from control, as determined by
ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs of columns
(p<0.05), obtained using GraphPad InStat 3 software. Vehicle n=13; 5 mg/kg/day
n=11; 50 mg/kg/day n=10.
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Figure III-4. Performance of old wild type mice in the Y-maze following
administration of tolfenamic acid. Tolfenamic acid was administered by oral gavage
daily for 34 days. See the methods section for details. Vehicle n=13; 5 mg/kg/day
n=11; 50 mg/kg/day n=10.
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Figure III-5. Treatment with tolfenamic acid reduces cortical Aβ plaque burden
in homozygous R1.40 mice. Tolfenamic acid was administered by oral gavage daily
for 34 days. See the methods section for details. A) Represents images of Aβ plaque
morphology and density in the cerebral cortex in different treatment groups after
immunohistochemical staining against Aβ using 6E10 antibody. CT TG = control
transgenic B) Quantification of total Aβ plaque area. “*” indicates that values are
significantly different from control, as determined by ANOVA analysis with TukeyKramer post-hoc test to compare all pairs of columns (∗p<0.05, ∗∗p<0.01), obtained
using GraphPad InStat 3 software. Vehicle n=5; 5 mg/kg/day n=7; 50 mg/kg/day n=5.
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